| Primary |
| Bone Marrow Conditioning Regimen |
18.2% |
| Prophylaxis |
18.2% |
| Stem Cell Transplant |
18.2% |
| Graft Versus Host Disease |
9.1% |
| Prophylaxis Against Graft Versus Host Disease |
9.1% |
| Bladder Cancer |
4.5% |
| Bone Marrow Transplant |
4.5% |
| Chemotherapy |
4.5% |
| Clostridial Infection |
4.5% |
| Convulsion Prophylaxis |
4.5% |
| Medulloblastoma |
4.5% |
|
| Blister |
9.1% |
| Burning Sensation |
9.1% |
| Confusional State |
9.1% |
| Drug Interaction |
9.1% |
| Hypothyroidism |
9.1% |
| Malignant Neoplasm Progression |
9.1% |
| Scleroderma |
9.1% |
| Stem Cell Transplant |
9.1% |
| Therapeutic Agent Toxicity |
9.1% |
| Toxic Epidermal Necrolysis |
9.1% |
| Venous Occlusion |
9.1% |
|
| Secondary |
| Stem Cell Transplant |
16.8% |
| Medulloblastoma |
12.9% |
| Acute Lymphocytic Leukaemia |
7.6% |
| Prophylaxis Against Graft Versus Host Disease |
7.2% |
| Bone Marrow Conditioning Regimen |
6.8% |
| Central Nervous System Lymphoma |
6.0% |
| Acute Myeloid Leukaemia |
5.2% |
| Neuroblastoma |
4.4% |
| Acute Leukaemia |
4.1% |
| Brain Neoplasm Malignant |
3.3% |
| Haematological Malignancy |
3.0% |
| Ewing's Sarcoma |
2.9% |
| Prophylaxis |
2.8% |
| Chemotherapy |
2.8% |
| Peripheral T-cell Lymphoma Unspecified |
2.8% |
| Bone Marrow Transplant |
2.5% |
| Non-hodgkin's Lymphoma |
2.4% |
| Primitive Neuroectodermal Tumour |
2.2% |
| Product Used For Unknown Indication |
2.2% |
| Infection |
2.0% |
|
| Sepsis |
11.9% |
| Venoocclusive Disease |
11.5% |
| Thrombocytopenia |
9.5% |
| Venoocclusive Liver Disease |
8.1% |
| Pyrexia |
6.1% |
| Vomiting |
6.1% |
| Stem Cell Transplant |
5.8% |
| Septic Shock |
4.7% |
| Acute Leukaemia |
4.4% |
| Renal Failure |
3.7% |
| Stomatitis |
3.4% |
| Bone Sarcoma |
3.1% |
| Graft Versus Host Disease |
3.1% |
| Neoplasm Malignant |
3.1% |
| Pneumonia |
3.1% |
| Mucosal Inflammation |
2.7% |
| Respiratory Failure |
2.7% |
| Dermatitis |
2.4% |
| Febrile Neutropenia |
2.4% |
| Infection |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.5% |
| Prophylaxis Against Graft Versus Host Disease |
13.0% |
| Bone Marrow Conditioning Regimen |
12.3% |
| Stem Cell Transplant |
11.3% |
| Acute Lymphocytic Leukaemia |
9.4% |
| Prophylaxis |
5.0% |
| Medulloblastoma |
3.3% |
| Metastases To Bone |
3.2% |
| Breast Cancer Metastatic |
2.7% |
| Graft Versus Host Disease |
2.7% |
| Cord Blood Transplant Therapy |
2.1% |
| Surgical Preconditioning |
2.0% |
| Bone Marrow Failure |
1.8% |
| Primitive Neuroectodermal Tumour |
1.8% |
| Bone Marrow Transplant |
1.7% |
| Breast Cancer |
1.5% |
| Immunosuppression |
1.5% |
| Prophylaxis Against Transplant Rejection |
1.5% |
| Chemotherapy |
1.4% |
| Autoimmune Thyroiditis |
1.4% |
|
| Venoocclusive Disease |
16.9% |
| Venoocclusive Liver Disease |
9.9% |
| Mucosal Inflammation |
6.4% |
| Post Transplant Lymphoproliferative Disorder |
6.4% |
| Sepsis |
6.4% |
| Thrombocytopenia |
6.4% |
| Somnolence |
5.8% |
| Death |
5.2% |
| Infection |
4.1% |
| Pleural Effusion |
3.5% |
| Thrombotic Microangiopathy |
3.5% |
| Vomiting |
3.5% |
| Weight Decreased |
3.5% |
| Wound Debridement |
3.5% |
| Renal Impairment |
2.9% |
| Stem Cell Transplant |
2.9% |
| Chronic Graft Versus Host Disease |
2.3% |
| Cytomegalovirus Infection |
2.3% |
| Drug Interaction |
2.3% |
| Gastric Cancer |
2.3% |
|
| Interacting |
|
|
